Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report

Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report

BackgroundDriver oncogene mutations, such as c-ros oncogene 1 (ROS1) and epidermal growth factor receptor (EGFR) were previously believed to be mutually exclusive in non-small cell lung cancer (NSCLC). Only sporadic cases of ROS1 and EGFR co-mutations have been reported. Hence, appropriate treatment...

Full description

Bibliographic Details
Main Authors: Zhiming Wu, Zelin Zhang, Dongdong Zhang, Zengyan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
EGFR
ROS1
tyrosine kinase inhibitors
co-mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1357230/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1357230/full

Similar Items